Citations (83)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Felix O. Okunlola, Fisayo A. Olotu & Mahmoud E. S. Soliman. (2022) Unveiling the mechanistic roles of chlorine substituted phthalazinone-based compounds containing chlorophenyl moiety towards the differential inhibition of poly (ADP-ribose) polymerase-1 in the treatment of lung cancer. Journal of Biomolecular Structure and Dynamics 40:21, pages 10878-10886.
Read now
Read now
Luigi Della Corte, Virginia Foreste, Claudia, Di Filippo, Pierluigi Giampaolino & Giuseppe Bifulco. (2021) Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know. Expert Opinion on Investigational Drugs 30:5, pages 543-554.
Read now
Read now
Marilyne Labrie, Nicholas D Kendsersky, Hongli Ma, Lydia Campbell, Jennifer Eng, Koei Chin & Gordon B Mills. (2019) Proteomics advances for precision therapy in ovarian cancer. Expert Review of Proteomics 16:10, pages 841-850.
Read now
Read now
Jarosław Przybycinski, Magdalena Nalewajska, Małgorzata Marchelek-Mysliwiec, Violetta Dziedziejko & Andrzej Pawlik. (2019) Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers. Expert Opinion on Therapeutic Targets 23:9, pages 773-785.
Read now
Read now
Laurence Booth, Jane L. Roberts, Rumeesa Rais, Andrew Poklepovic & Paul Dent. (2018) Valproate augments Niraparib killing of tumor cells. Cancer Biology & Therapy 19:9, pages 797-808.
Read now
Read now
Articles from other publishers (78)
Yihua Liu, Li Zheng, Xingjuan Cai, Xiaojun Zhang & Yang Ye. (2023) Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery. Frontiers in Cardiovascular Medicine 10.
Crossref
Crossref
Maaike A. C. Bruin, Gabe S. Sonke, Jos H. Beijnen & Alwin D. R. Huitema. (2022) Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology. Clinical Pharmacokinetics 61:12, pages 1649-1675.
Crossref
Crossref
Anna Sefer, Eleni Kallis, Tobias Eilert, Carlheinz Röcker, Olga Kolesnikova, David Neuhaus, Sebastian Eustermann & Jens Michaelis. (2022) Structural dynamics of DNA strand break sensing by PARP-1 at a single-molecule level. Nature Communications 13:1.
Crossref
Crossref
Weitao Tao, Siqi Wang, Alei Xu, Yangyang Xue, Hui Wang & Huiqin Xu. (2022) 18F-FDG Micro PET/CT imaging to evaluate the effect of BRCA1 knockdown on MDA-MB231 breast cancer cell radiosensitivity. Translational Oncology 25, pages 101517.
Crossref
Crossref
Stergios Boussios, Elie Rassy, Michele Moschetta, Aruni Ghose, Sola Adeleke, Elisabet Sanchez, Matin Sheriff, Cyrus Chargari & Nicholas Pavlidis. (2022) BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside. Cancers 14:16, pages 3888.
Crossref
Crossref
Tatyana A. Kurgina, Stanislav I. Shram, Mikhail M. Kutuzov, Tatyana V. Abramova, Tatyana A. Shcherbakova, Ekaterina A. Maltseva, Vladimir V. Poroikov, Olga I. Lavrik, Vytas K. Švedas & Dmitry K. Nilov. (2022) Inhibitory Effects of 7-Methylguanine and Its Metabolite 8-Hydroxy-7-Methylguanine on Human Poly(ADP-Ribose) Polymerase 1. Biochemistry (Moscow) 87:8, pages 823-831.
Crossref
Crossref
Jia Zeng, Jifa Zhang, Ying Sun, Jiaxing Wang, Changyu Ren, Souvik Banerjee, Liang Ouyang & Yuxi Wang. (2022) Targeting EZH2 for cancer therapy: From current progress to novel strategies. European Journal of Medicinal Chemistry 238, pages 114419.
Crossref
Crossref
Ling Yu, Zhi-wei Yan, You-de Wang, Hao Miao, Jing-yi Zhao, Chong Pang & Shuai Li. (2022) Recent advances in structural types and medicinal chemistry of PARP-1 inhibitors. Medicinal Chemistry Research 31:8, pages 1265-1276.
Crossref
Crossref
Kirill Kirsanov, Timur Fetisov, Elena Antoshina, Lubov Trukhanova, Tatiana Gor’kova, Olga Vlasova, Irina Khitrovo, Ekaterina Lesovaya, Nataliya Kulbachevskaya, Tatiana Shcherbakova, Gennady Belitsky, Marianna Yakubovskaya, Vytas Švedas & Dmitry Nilov. (2022) Toxicological Properties of 7-Methylguanine, and Preliminary Data on its Anticancer Activity. Frontiers in Pharmacology 13.
Crossref
Crossref
Aruni Ghose, Sri Vidya Niharika Gullapalli, Naila Chohan, Anita Bolina, Michele Moschetta, Elie Rassy & Stergios Boussios. (2022) Applications of Proteomics in Ovarian Cancer: Dawn of a New Era. Proteomes 10:2, pages 16.
Crossref
Crossref
Erina Takai, Hiromi Nakamura, Suenori Chiku, Emi Kubo, Akihiro Ohmoto, Yasushi Totoki, Tatsuhiro Shibata, Ryota Higuchi, Masakazu Yamamoto, Junji Furuse, Kyoko Shimizu, Hideaki Takahashi, Chigusa Morizane, Toru Furukawa & Shinichi Yachida. (2022) Whole-exome Sequencing Reveals New Potential Susceptibility Genes for Japanese Familial Pancreatic Cancer. Annals of Surgery 275:4, pages e652-e658.
Crossref
Crossref
Xinyue Hu, Jifa Zhang, Ya Zhang, Fulun Jiao, Jiaxing Wang, Hao Chen, Liang Ouyang & Yuxi Wang. (2022) Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: Advances, challenges, and opportunities. European Journal of Medicinal Chemistry 230, pages 114094.
Crossref
Crossref
Su-Jin Koh, Shozo Ohsumi, Masato Takahashi, Eisuke Fukuma, Kyung Hae Jung, Takanori Ishida, Ming-Shen Dai, Chuan-Hsun Chang, Tapashi Dalvi, Graham Walker, James Bennett, Joyce O’Shaughnessy & Judith Balmaña. (2021) Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study. Breast Cancer 29:1, pages 92-102.
Crossref
Crossref
William D.J. Tremlett, David M. Goodman, Tasha R. Steel, Saawan Kumar, Anna Wieczorek-Błauż, Fearghal P. Walsh, Matthew P. Sullivan, Muhammad Hanif & Christian G. Hartinger. (2021) Design concepts of half-sandwich organoruthenium anticancer agents based on bidentate bioactive ligands. Coordination Chemistry Reviews 445, pages 213950.
Crossref
Crossref
Anusha Vaidyanathan & Virginia Kaklamani. (2021) Understanding the Clinical Implications of Low Penetrant Genes and Breast Cancer Risk. Current Treatment Options in Oncology 22:10.
Crossref
Crossref
Joseph M. Gozgit, Melissa M. Vasbinder, Ryan P. Abo, Kaiko Kunii, Kristy G. Kuplast-Barr, Bin Gui, Alvin Z. Lu, Jennifer R. Molina, Elena Minissale, Kerren K. Swinger, Tim J. Wigle, Danielle J. Blackwell, Christina R. Majer, Yue Ren, Mario Niepel, Zacharenia A. Varsamis, Sunaina P. Nayak, Ellen Bamberg, Jan-Rung Mo, W. David Church, Ahmed S.A. Mady, Jeff Song, Luke Utley, Patricia E. Rao, Timothy J. Mitchison, Kevin W. Kuntz, Victoria M. Richon & Heike Keilhack. (2021) PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. Cancer Cell 39:9, pages 1214-1226.e10.
Crossref
Crossref
Matthews M. Malka, Julia Eberle, Kathrin Niedermayer, Darius P. Zlotos & Lisa Wiesmüller. (2021) Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells. Biomolecules 11:7, pages 981.
Crossref
Crossref
Garri Manasaryan, Dmitry Suplatov, Sergey Pushkarev, Viktor Drobot, Alexander Kuimov, Vytas Švedas & Dmitry Nilov. (2021) Bioinformatic Analysis of the Nicotinamide Binding Site in Poly(ADP-Ribose) Polymerase Family Proteins. Cancers 13:6, pages 1201.
Crossref
Crossref
Oksana V. Salomatina, Irina I. Popadyuk, Alexandra L. Zakharenko, Olga D. Zakharova, Arina A. Chepanova, Nadezhda.S. Dyrkheeva, Nina I. Komarova, Jóhannes Reynisson, Rashid O. Anarbaev, Nariman F. Salakhutdinov, Olga I. Lavrik & Konstantin P. Volcho. (2021) Deoxycholic acid as a molecular scaffold for tyrosyl-DNA phosphodiesterase 1 inhibition: A synthesis, structure–activity relationship and molecular modeling study. Steroids 165, pages 108771.
Crossref
Crossref
Razan Sheta, Magdalena Bachvarova, Marie Plante, Marie-Claude Renaud, Alexandra Sebastianelli, Jean Gregoire, Jamilet Miranda Navarro, Ricardo Bringas Perez, Jean-Yves Masson & Dimcho Bachvarov. (2020) Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy. Journal of Translational Medicine 18:1.
Crossref
Crossref
Carolina Velázquez, Enrique Lastra, Francisco Avila Cobos, Luis Abella, Virginia de la Cruz, Blanca Ascensión Hernando, Lara Hernández, Noemí Martínez, Mar Infante & Mercedes Durán. (2020) A comprehensive custom panel evaluation for routine hereditary cancer testing: improving the yield of germline mutation detection. Journal of Translational Medicine 18:1.
Crossref
Crossref
Heng Zhu, Miaoyan Wei, Jin Xu, Jie Hua, Chen Liang, Qingcai Meng, Yiyin Zhang, Jiang Liu, Bo Zhang, Xianjun Yu & Si Shi. (2020) PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Molecular Cancer 19:1.
Crossref
Crossref
Ewa Przybytkowski, Thomas Davis, Abdelrahman Hosny, Julia Eismann, Ursula A. Matulonis, Gerburg M. Wulf & Sheida Nabavi. (2020) An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers. BMC Cancer 20:1.
Crossref
Crossref
Bulent Cetin, Chiara A. Wabl & Ozge Gumusay. (2020) The DNA damaging revolution. Critical Reviews in Oncology/Hematology 156, pages 103117.
Crossref
Crossref
Ye Han, Xiaopeng Yu, Shuqiang Li, Ye Tian & Caigang Liu. (2020) New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer. Frontiers in Oncology 10.
Crossref
Crossref
Yue Zhao, Liu-Xia Zhang, Ting Jiang, Jing Long, Zhong-Ye Ma, Ai-Ping Lu, Yan Cheng & Dong-Sheng Cao. (2020) The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy–Current progress and future direction. European Journal of Medicinal Chemistry 203, pages 112570.
Crossref
Crossref
Konstantinos Agiannitopoulos, Eirini Papadopoulou, Georgios N. Tsaousis, Georgia Pepe, Stavroula Kampouri, Eleni Patsea, George Lypas & George Nasioulas. (2020)
Report of a germline double heterozygote in
MSH2
and
PALB2
. Molecular Genetics & Genomic Medicine 8:10.
Crossref
Crossref
Taru A. Muranen, Sofia Khan, Rainer Fagerholm, Kristiina Aittomäki, Julie M. Cunningham, Joe Dennis, Goska Leslie, Lesley McGuffog, Michael T. Parsons, Jacques Simard, Susan Slager, Penny Soucy, Douglas F. Easton, Marc Tischkowitz, Amanda B. Spurdle, Rita K. Schmutzler, Barbara Wappenschmidt, Eric Hahnen, Maartje J. Hooning, Christian F. Singer, Gabriel Wagner, Mads Thomassen, Inge Sokilde Pedersen, Susan M. Domchek, Katherine L. Nathanson, Conxi Lazaro, Caroline Maria Rossing, Irene L. Andrulis, Manuel R. Teixeira, Paul James, Judy Garber, Jeffrey N. Weitzel, Anna Jakubowska, Drakoulis Yannoukakos, Esther M. John, Melissa C. Southey, Marjanka K. Schmidt, Antonis C. Antoniou, Georgia Chenevix-Trench, Carl Blomqvist & Heli Nevanlinna. (2020) Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. npj Breast Cancer 6:1.
Crossref
Crossref
Marijana Pavlović, Ana Tadić, Nevenka Gligorijević, Jelena Poljarević, Tamara Petrović, Biljana Dojčinović, Aleksandar Savić, Siniša Radulović, Sanja Grgurić-Šipka & Sandra Aranđelović. (2020) Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells. Journal of Inorganic Biochemistry 210, pages 111155.
Crossref
Crossref
Huanbo Zhu, Umang Swami, Ranjan Preet & Jun Zhang. (2020) Harnessing DNA Replication Stress for Novel Cancer Therapy. Genes 11:9, pages 990.
Crossref
Crossref
Stergios Boussios, Charlotte Abson, Michele Moschetta, Elie Rassy, Afroditi Karathanasi, Tahir Bhat, Faisal Ghumman, Matin Sheriff & Nicholas Pavlidis. (2020) Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond. Drugs in R&D 20:2, pages 55-73.
Crossref
Crossref
Harriet E. D. Southgate, Lindi Chen, Nicola J. Curtin & Deborah A. Tweddle. (2020) Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma. Frontiers in Oncology 10.
Crossref
Crossref
Emily R Hennes, Elizabeth N Dow-Hillgartner, Jason J Bergsbaken & Jennifer K Piccolo. (2020) PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost. Journal of Oncology Pharmacy Practice 26:3, pages 718-729.
Crossref
Crossref
Francesco Gentile, Ahmed H. Elmenoufy, Gloria Ciniero, David Jay, Feridoun Karimi‐Busheri, Khaled H. Barakat, Michael Weinfeld, Frederick G. West & Jack A. Tuszynski. (2020) Computer‐aided drug design of small molecule inhibitors of the ERCC1‐XPF protein–protein interaction. Chemical Biology & Drug Design 95:4, pages 460-471.
Crossref
Crossref
Surintorn Boonanuntanasarn, Araya Jangprai & Uthairat Na-Nakorn. (2020) Transcriptomic analysis of female and male gonads in juvenile snakeskin gourami (Trichopodus pectoralis). Scientific Reports 10:1.
Crossref
Crossref
Dmitry Nilov, Natalya Maluchenko, Tatyana Kurgina, Sergey Pushkarev, Alexandra Lys, Mikhail Kutuzov, Nadezhda Gerasimova, Alexey Feofanov, Vytas Švedas, Olga Lavrik & Vasily M. Studitsky. (2020) Molecular Mechanisms of PARP-1 Inhibitor 7-Methylguanine. International Journal of Molecular Sciences 21:6, pages 2159.
Crossref
Crossref
Guosheng Su, Lihua Qin, Xiaoye Su, Chuanmin Tao & Yesheng Wei. (2020) Gender‐dependent pharmacokinetics of olaparib in rats determined by ultra‐high performance liquid chromatography/electrospray ionization tandem mass spectrometry. Biomedical Chromatography 34:3.
Crossref
Crossref
Ling Wang, Qi Wang, Yangchun Xu, Manhua Cui & Liying Han. (2020) Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance. Current Drug Targets 21:2, pages 167-178.
Crossref
Crossref
Jian Zhang, Hong Zheng, Yunong Gao, Ge Lou, Rutie Yin, Dongmei Ji, Wenhua Li, Wei Wang, Bairong Xia, Danqing Wang, Jianmei Hou, James Yan, Yongjiang Hei, Zhi-Yi Zhang, Ashley Milton & Xiaohua Wu. (2020) Phase I Pharmacokinetic Study of Niraparib in Chinese Patients with Epithelial Ovarian Cancer. The Oncologist 25:1, pages 19-e10.
Crossref
Crossref
Kevin J. Lee, Elise Mann, Griffin Wright, Cortt G. Piett, Zachary D. Nagel & Natalie R. Gassman. (2020) Exploiting DNA repair defects in triple negative breast cancer to improve cell killing. Therapeutic Advances in Medical Oncology 12, pages 175883592095835.
Crossref
Crossref
Yuliya V. Sherstyuk, Nikita V. Ivanisenko, Alexandra L. Zakharenko, Maria V. Sukhanova, Roman Y. Peshkov, Ilia V. Eltsov, Mikhail M. Kutuzov, Tatiana A. Kurgina, Ekaterina A. Belousova, Vladimir A. Ivanisenko, Olga I. Lavrik, Vladimir N. Silnikov & Tatyana V. Abramova. (2019) Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3. International Journal of Molecular Sciences 21:1, pages 214.
Crossref
Crossref
Clémence Dubois, Fanny Martin, Chervin Hassel, Florian Magnier, Pierre Daumar, Corinne Aubel, Sylvie Guerder, Emmanuelle Mounetou, Frédérique Penault-Lorca & Mahchid Bamdad. (2019) Low-Dose and Long-Term Olaparib Treatment Sensitizes MDA-MB-231 and SUM1315 Triple-Negative Breast Cancers Spheroids to Fractioned Radiotherapy. Journal of Clinical Medicine 9:1, pages 64.
Crossref
Crossref
Tatyana M. Khomenko, Alexandra L. Zakharenko, Arina A. Chepanova, Ekaterina S. Ilina, Olga D. Zakharova, Vasily I. Kaledin, Valeriy P. Nikolin, Nelly A. Popova, Dina V. Korchagina, Jóhannes Reynisson, Raina Chand, Daniel M. Ayine-Tora, Jinal Patel, Ivanhoe K. H. Leung, Konstantin P. Volcho, Nariman F. Salakhutdinov & Olga I. Lavrik. (2019) Promising New Inhibitors of Tyrosyl-DNA Phosphodiesterase I (Tdp 1) Combining 4-Arylcoumarin and Monoterpenoid Moieties as Components of Complex Antitumor Therapy. International Journal of Molecular Sciences 21:1, pages 126.
Crossref
Crossref
Stephanie Lheureux, Mansoor Mirza & Robert Coleman. (2019) The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers. Journal of Clinical Oncology 37:27, pages 2449-2459.
Crossref
Crossref
Xiangning Bu, Jiro Kato & Joel Moss. (2019) Emerging roles of ADP-ribosyl-acceptor hydrolases (ARHs) in tumorigenesis and cell death pathways. Biochemical Pharmacology 167, pages 44-49.
Crossref
Crossref
Marta Betti, Anna Aspesi, Marika Sculco, Giuseppe Matullo, Corrado Magnani & Irma Dianzani. (2019) Genetic predisposition for malignant mesothelioma: A concise review. Mutation Research/Reviews in Mutation Research 781, pages 1-10.
Crossref
Crossref
Sarah A. Cook & Anna V. Tinker. (2019) PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review. BioDrugs 33:3, pages 255-273.
Crossref
Crossref
Diansong Zhou, Jianguo Li, Maria Learoyd, Khanh Bui, Alienor Berges, Tsveta Milenkova, Nidal Al‐Huniti, Helen Tomkinson & Hongmei Xu. (2019) Efficacy and Safety Exposure‐Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients. Clinical Pharmacology & Therapeutics 105:6, pages 1492-1500.
Crossref
Crossref
Marilyne Labrie, Tae-Beom Kim, Zhenlin Ju, Sanghoon Lee, Wei Zhao, Yong Fang, Yiling Lu, Ken Chen, Pedro Ramirez, Michael Frumovitz, Larissa Meyer, Nicole D. Fleming, Anil K. Sood, Robert L. Coleman, Gordon B. Mills & Shannon N. Westin. (2019) Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget 10:37, pages 3533-3546.
Crossref
Crossref
Masaaki Yamamoto, Caining Jin, Tsuyoshi Hata, Yota Yasumizu, Yan Zhang, Deli Hong, Takahiro Maeda, Masaaki Miyo, Masayuki Hiraki, Yozo Suzuki, Kunihiko Hinohara, Hasan Rajabi & Donald Kufe. (2019) MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells. Cancer Research 79:8, pages 2031-2041.
Crossref
Crossref
Samuele Lodovichi, Alberto Mercatanti, Tiziana Cervelli & Alvaro Galli. (2019)
Computational analysis of data from a genome-wide screening identifies new
PARP1
functional interactors as potential therapeutic targets
. Oncotarget 10:28, pages 2722-2737.
Crossref
Crossref
Ewa Gogola, Sven RottenbergJos Jonkers. (2019) Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated Cancer. Annual Review of Cancer Biology 3:1, pages 235-254.
Crossref
Crossref
Priyancy G. Jain & Bhumika D. Patel. (2019) Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update. European Journal of Medicinal Chemistry 165, pages 198-215.
Crossref
Crossref
Yuma Nonomiya, Kohji Noguchi, Kazuhiro Katayama & Yoshikazu Sugimoto. (2019) Novel pharmacological effects of poly (ADP-ribose) polymerase inhibitor rucaparib on the lactate dehydrogenase pathway. Biochemical and Biophysical Research Communications 510:4, pages 501-507.
Crossref
Crossref
Masato Mashimo, Xiangning Bu, Kazumasa Aoyama, Jiro Kato, Hiroko Ishiwata-Endo, Linda A. Stevens, Atsushi Kasamatsu, Lynne A. Wolfe, Camilo Toro, David Adams, Thomas Markello, William A. Gahl & Joel Moss. (2019) PARP1 inhibition alleviates injury in ARH3-deficient mice and human cells. JCI Insight 4:4.
Crossref
Crossref
Akihiro Ohmoto, Shinichi Yachida & Chigusa Morizane. (2019) Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. International Journal of Molecular Sciences 20:3, pages 561.
Crossref
Crossref
Reece G. Kenny & Celine J. Marmion. (2019) Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?. Chemical Reviews 119:2, pages 1058-1137.
Crossref
Crossref
Anna Aspesi, Marika Sculco, Simonetta Guarrera, Elisabetta Casalone, Laura Moro, Corrado Magnani, Giuseppe Matullo & Irma Dianzani. 2019. Mesothelioma. Mesothelioma
45
67
.
Hideyuki HAYASHI. (2018) Clinical sequencing of pancreatic cancer in clinical practice実地医療における膵がんクリニカルシークエンス. Suizo 33:6, pages 915-922.
Crossref
Crossref
Brittany Haynes, Junko Murai & Jung-Min Lee. (2018) Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. Cancer Treatment Reviews 71, pages 1-7.
Crossref
Crossref
Dong Li, Jingyan Yang, Huanzhi Ma, Chengliang Sun & Rongjie Feng. (2018)
Retracted
: Inositol polyphosphate‐4‐phosphatase type II and rucaparib treatment inhibit the growth of osteosarcoma cells dependent on phosphoinositide 3‐kinase/protein kinase B pathway
. Journal of Cellular Biochemistry 119:12, pages 9899-9909.
Crossref
Crossref
Junior Gonzales, Susanne Kossatz, Sheryl Roberts, Giacomo Pirovano, Christian Brand, Carlos Pérez-Medina, Patrick Donabedian, M. Jason de la Cruz, Willem J. M. Mulder & Thomas Reiner. (2018) Nanoemulsion-Based Delivery of Fluorescent PARP Inhibitors in Mouse Models of Small Cell Lung Cancer. Bioconjugate Chemistry 29:11, pages 3776-3782.
Crossref
Crossref
Margarita Romeo, Juan Pardo, Anna Martínez-Cardús, Eva Martínez-Balibrea, Vanesa Quiroga, Sergio Martínez-Román, Francesc Solé, Mireia Margelí & Ricard Mesía. (2018) Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer. International Journal of Molecular Sciences 19:10, pages 3249.
Crossref
Crossref
Sana D. Karam, Krishna Reddy, Patrick J. Blatchford, Tim Waxweiler, Alicia M. DeLouize, Ayman Oweida, Hilary Somerset, Carrie Marshall, Christian Young, Kurtis D. Davies, Madeleine Kane, Aik Choo Tan, Xiao Jing Wang, Antonio Jimeno, Dara L. Aisner, Daniel W. Bowles & David Raben. (2018) Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. Clinical Cancer Research 24:20, pages 4949-4959.
Crossref
Crossref
Ilaria Plantamura, Giulia Cosentino & Alessandra Cataldo. (2018) MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers. Frontiers in Oncology 8.
Crossref
Crossref
Pasquale Rescigno, Robert Chandler & Johann de Bono. (2018) Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer. Current Opinion in Supportive & Palliative Care 12:3, pages 339-343.
Crossref
Crossref
Marwa Elamin, David N. Ruskin, Susan A. Masino & Paola Sacchetti. (2018) Ketogenic Diet Modulates NAD+-Dependent Enzymes and Reduces DNA Damage in Hippocampus. Frontiers in Cellular Neuroscience 12.
Crossref
Crossref
Jianfeng Li, David Svilar, Steven McClellan, Jung-Hyun Kim, Eun-Young Erin Ahn, Conchita Vens, David M. WilsonIIIIII & Robert W. Sobol. (2018) DNA Repair Molecular Beacon assay: a platform for real-time functional analysis of cellular DNA repair capacity. Oncotarget 9:60, pages 31719-31743.
Crossref
Crossref
Jone Michelena, Aleksandra Lezaja, Federico Teloni, Thomas Schmid, Ralph Imhof & Matthias Altmeyer. (2018) Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance. Nature Communications 9:1.
Crossref
Crossref
Xin Wang, Yaqin Shi, Doudou Huang & Xiaoxiang Guan. (2018) Emerging therapeutic modalities of PARP inhibitors in breast cancer. Cancer Treatment Reviews 68, pages 62-68.
Crossref
Crossref
Shoko Vos, Paul Joannes van Diest & Cathy Beatrice Moelans. (2018) A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?. Critical Reviews in Oncology/Hematology 127, pages 29-41.
Crossref
Crossref
Federica Fratangelo, Rosa Camerlingo, Maria Vincenza Carriero, Giuseppe Pirozzi, Giuseppe Palmieri, Giusy Gentilcore, Concetta Ragone, Michele Minopoli, Paolo Antonio Ascierto & Maria Letizia Motti. (2018) Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells. International Journal of Oncology.
Crossref
Crossref
Hossein PashaiefarMarjan YaghmaieJavad Tavakkoly-BazzazSeyed Hamid GhaffariKamran AlimoghaddamMajid MomenyPantea IzadiMarzie IzadifardAmir KasaeianArdeshir Ghavamzadeh. (2018)
PARP-1
Overexpression as an Independent Prognostic Factor in Adult Non-M3 Acute Myeloid Leukemia
. Genetic Testing and Molecular Biomarkers 22:6, pages 343-349.
Crossref
Crossref
Marios Papadimitriou, Giannis Mountzios & Christos A. Papadimitriou. (2018) The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality. Cancer Treatment Reviews 67, pages 34-44.
Crossref
Crossref
Ewa Gogola, Alexandra A. Duarte, Julian R. de Ruiter, Wouter W. Wiegant, Jonas A. Schmid, Roebi de Bruijn, Dominic I. James, Sergi Guerrero Llobet, Daniel J. Vis, Stefano Annunziato, Bram van den Broek, Marco Barazas, Ariena Kersbergen, Marieke van de Ven, Madalena Tarsounas, Donald J. Ogilvie, Marcel van Vugt, Lodewyk F.A. Wessels, Jirina Bartkova, Irina Gromova, Miguel Andújar-Sánchez, Jiri Bartek, Massimo Lopes, Haico van Attikum, Piet Borst, Jos Jonkers & Sven Rottenberg. (2018) Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality. Cancer Cell 33:6, pages 1078-1093.e12.
Crossref
Crossref
Ornella Franzese, Fiorenzo Battaini, Grazia Graziani, Lucio Tentori, Maria Luisa Barbaccia, Angelo Aquino, Mario Roselli, Maria Pia Fuggetta, Enzo Bonmassar & Francesco Torino. (2018) Drug-induced xenogenization of tumors: A possible role in the immune control of malignant cell growth in the brain?. Pharmacological Research 131, pages 1-6.
Crossref
Crossref
Sander Frank, Peter Nelson & Valeri Vasioukhin. (2018) Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects. F1000Research 7, pages 1173.
Crossref
Crossref
Ilsa T. Kirby & Michael S. Cohen. 2019. Activity-Based Protein Profiling. Activity-Based Protein Profiling
211
231
.